Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer
Phase II Evaluation of Gleevec Combined With Camptosar Plus Paraplatin in Patients With Previously Untreated Extensive Stage SCLC
3 other identifiers
interventional
60
0 countries
N/A
Brief Summary
This study will evaluate combination chemotherapy for patients with extensive stage small cell lung cancer combined with the potentially useful growth inhibiting effects of Gleevec.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_2 lung-cancer
Started Sep 2002
Typical duration for phase_2 lung-cancer
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2002
CompletedFirst Submitted
Initial submission to the registry
September 12, 2005
CompletedFirst Posted
Study publicly available on registry
September 19, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2007
CompletedJune 28, 2010
January 1, 2008
5.3 years
September 12, 2005
June 24, 2010
Conditions
Outcome Measures
Primary Outcomes (2)
Overall response rate
Response duration
Secondary Outcomes (2)
Time to progression
Overall toxicity
Interventions
Eligibility Criteria
You may qualify if:
- To be included in this study, you must meet the following criteria:
- Small cell lung cancer with extensive stage disease confirmed by biopsy
- Measurable or evaluable disease
- Ability to perform activities of daily living with minimal assistance
- Adequate bone marrow, liver and kidney
- No active brain metastasis.
- No previous chemotherapy or radiation therapy
- Give written informed consent.
You may not qualify if:
- You cannot participate in this study if any of the following apply to you:
- Limited stage disease (includes IA, IB, IIA, IIB, and IIIA)
- Active brain metastasis
- Age \< 18 years old
- History of a prior malignancy within three years
- Women pregnant or lactating.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- SCRI Development Innovations, LLClead
- Novartiscollaborator
- Pharmacia and Upjohncollaborator
Related Publications (1)
Spigel DR, Hainsworth JD, Simons L, Meng C, Burris HA 3rd, Yardley DA, Grapski R, Schreeder M, Mallidi PV, Greco FA; Minnie Pearl Cancer Research Network. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. J Thorac Oncol. 2007 Sep;2(9):854-61. doi: 10.1097/JTO.0b013e31814617b7.
PMID: 17805064RESULT
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Anthony Greco, MD
SCRI Development Innovations, LLC
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
September 12, 2005
First Posted
September 19, 2005
Study Start
September 1, 2002
Primary Completion
December 1, 2007
Study Completion
December 1, 2007
Last Updated
June 28, 2010
Record last verified: 2008-01